SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, Kohler JA, Furst DE 1994 Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events. Am J Med 96: 115123.
  • 2
    Meunier PJ, Dempster DW, Edouard C, Chapuy MC, Arlot M, Charhon S 1984 Bone histomorphometry in corticosteroid-inducedcushing's syndrome. In: AvioliLV, GennariC, ImbimboB (eds.) Glucocorticoid EffectsTheir Biological Consequences. Plenum Publishing, U.S.A., pp. 191200.
  • 3
    Dempster DW 1989 Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 4: 137141.
  • 4
    Luckert B 1996 Glucocorticoid-induced osteoporosis. In: MarcusR, FeldmanD, KelseyJ (eds.) Osteoporosis. Academic Press, New York, NY, U.S.A., pp. 801820.
  • 5
    Bressot C, Meunier PJ, Chapuy MC, Lejeune E, Edouard C, Darby AJ 1979 Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis. Calcif Tissue Int 1: 303311.
  • 6
    Meunier PJ 1993 Is steroid-induced osteoporosis preventable? N Engl J Med 328: 17811782.
  • 7
    Fleisch H 1998 Bisphosphonates: Mechanisms of action. Endocr Rev 19: 80100.
  • 8
    Liberman UA, Weiss SR, Bröll J, Minne H, Quan NH, Bell NH, Rodrigez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333: 14371443.
  • 9
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 15351541.
  • 10
    McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, El Hajj Fuleihan G, Reda C, Yates AJ, Ravn P 1998 Alendronate prevents postmenopausal bone loss in women without osteoporosis: A double-blind, randomized, controlled trial. Ann Intern Med 28: 523561.
  • 11
    Hosking D, Chilvers CED, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ 1998 Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 338: 485492.
  • 12
    Adami S, Passeri M, Orolani S, Broggini M, Carratelli L, Caruso I, Gandolini G, Gnessi L, Laurenzi M, Lombardi A, Norbiato G, Pryor-Tillotson S, Reda C, Romanini L, Subrizi D, Wei L, Yates AJ 1995 Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 17: 383390.
  • 13
    Chesnut CH, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, Uma K, Pryor-Tillotson S, Santora AC 1995 Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med 99: 144152.
  • 14
    Devogelaer JP, Broll H, Correa-Rotter R, Comming DC, Nagant De Deuxchaisnes C, Geusens P, Hosking D, Jaeger P, Kaufman JM, Leite M, Leon J, Liberman U, Menkes CJ, Meunier PJ, Reid I, Rodriguez J, Romanowicz A, Seeman E, Vemeulen A, Hirsch LJ, Lombardi A, Plezia K, Santora AC, Yates AJ, Yuan W 1996 Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 18: 141150.
  • 15
    Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC 1996 Effect of three-years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101: 488501.
  • 16
    Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC, Adami S, Harris ST, Santora AC, Hirsch LJ, Oppenheimer L, Thompson D 1997 Prevention of nonvertebral fractures by alendronate: A meta-analysis. JAMA 277: 11591164.
  • 17
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barre H, Connor E, Musliner TA, Palermo L, Prisneas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280: 20772082.
  • 18
    Pols HAP, for the FOSIT Study Group 1999 A multinational, placebo-controlled randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 9: 461468.
  • 19
    Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100: 14751480.
  • 20
    Bone HG, Downs RW Jr, Tucci JR., Harris ST, Weinstein RS, Licata AA, McClung MR, Kimmel DB, Gertz BJ, Hale E, Polvino WJ 1997 Dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab 82: 265274.
  • 21
    Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79: 16931700.
  • 22
    Saag KG, Emkey R, Schnitzer T, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339: 292299.
  • 23
    Parfitt AM, Drezner MK, Glorieux F, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2: 595610.
  • 24
    Roux JP, Arlot ME, Gineyts E, Meunier PJ, Delmas PD 1995 Automatic interactive measurement of resorption cavities in transiliac bone biopsies and correlation with deoxypyridinoline. Bone 17: 153156.
  • 25
    Parfitt AM 1983 The physiologicalclinical significance of bone histomorphometric data. In: ReckerR (ed.) Bone Histomorphometry: TechniquesInterpretations. CRC Press, Boca Raton, FL, U.S.A., pp. 143223.
  • 26
    Chavassieux PM, Arlot ME, Meunier PJ 1985 Intermethod variation in bone histomorphometry: Comparison between manual and computerized methods applied to iliac bone biopsies. Bone 6: 221229.
  • 27
    Dempster DW, Arlot MA, Meunier PJ 1983 Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 35: 410417.
  • 28
    Meunier P, Courpron P 1973 Iliac trabecular bone volume in 236 controls: Representativeness of iliac samples. In: JaworskyZFG (ed.) Proceedings of the First Workshop on Bone Morphometry. University of Ottawa Press, Ottawa, Canada, pp. 100105.
  • 29
    Vedi S, Compston JE, Webb A, Tighe JR 1982 Histomorphometric analysis of bone biopsies from the iliac crest of normal British subjects. Metab Bone Dis Rel Res 4: 231236.
  • 30
    Lips P, Courpron P, Meunier PJ 1978 Mean wall thickness of trabecular packets in the human iliac crest: Changes with age. Calcif Tissue Res 26: 1317.
  • 31
    Melsen F, Mosekilde L 1978 Tetracycline double labeling of iliac trabecular bone in 41 normal adults. Calcif Tissue Res 26: 99102.
  • 32
    Manolagas SC, Weinstein RS 1999 New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 14: 10611066.
  • 33
    Chappard D, Legrand E, Basle MF, Fromont P, Racineux JL, Rebel A, Audran M 1996 Altered trabecular architecture induced by corticosteroids: A bone histomorphometric study. J Bone Miner Res 11: 676685.
  • 34
    Parfitt AM 1992 The physiologicpathogenetic significance of bone histomorphometric data. In: CoeFL, FavusMJ (eds.) Disorders of BoneMineral Metabolism. Raven Press, New York, NY, U.S.A., pp. 475489.
  • 35
    Parfitt AM 1990 Osteomalaciarelated disorders. In: AvioliLV, KraneSM (eds.) Metabolic Bone DiseaseRelated Disorders. W.B. Saunders, Philadelphia, PA, U.S.A., pp. 329396.
  • 36
    Reid IR, Nicholson GC, Weinstein RS, Hosking DJ, Cundy T, Kotowicz MA, Murphy WA, Yeap S, Dufresne S, Lombardi A, Musliner TA, Thompson DE, Yates AJ 1996 Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized placebo-controlled trial. Am J Med 171: 341348.
  • 37
    Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, Lyles K, McIlwain H, Murphy WA Jr, Reda C, Rude R, Seton M, Tiegs R, Thompson D, Tucci JR, Yates AJ, Zimering M 1996 Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 81: 961967.
  • 38
    Stock JL, Bell NH, Chesnutt III CH, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora II AC 1997 Increment in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 103: 291297.
  • 39
    Balena R, Toolan BC, Shea M, Markatos M, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Franenfield D, Quartuccio H, Fioravanti C, Clair J, Brown E, Hayes WC, Rodan GA 1993 The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92: 25772586.
  • 40
    Meunier PJ, Boivin G 1997 Bone mineral reflects bone mass but also the degree of mineralization of bone: therapeutic implications. Bone 21: 373377.
  • 41
    Roschger P, Fratzl P, Klaushofer K, Rodan G 1997 Mineralization of cancellous bone after alendronate and sodium fluoride treatment: A quantitative backscattered electron imaging study on minipig ribs. Bone 20: 393397.
  • 42
    Boivin G, Klaushofer K, Roschger P, Rinnerthaler S, Fratzl P, Chavassieux P, Santora AC, Yates AJ, Meunier PJ 1998 Alendronate increases the mean degree of mineralization of bone and the uniformity of mineralization of bone in osteoporotic women. Bone 23(Suppl 5): F282.